Quantitative drug interactions prediction system (Q-DIPS): A dynamic computer-based method to assist in the choice of clinically relevant in vivo studies

Clinical Pharmacokinetics

Volumn 40, Issue 9, 2001, Pages 631-640

  Bonnabry, Pascal ^a   Sievering, Johann ^a   Leemann, Thierry ^a   Dayer, Pierre ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ACENOCOUMAROL; ALFENTANIL; ALPRAZOLAM; AMIODARONE; AMITRIPTYLINE; AMPRENAVIR; ASTEMIZOLE; BROMOCRIPTINE; BUPRENORPHINE; BUSPIRONE; CARBAMAZEPINE; CARMUSTINE; CELECOXIB; CHLORPROMAZINE; CISAPRIDE; CITALOPRAM; CLARITHROMYCIN; CLOMIPRAMINE; CLONAZEPAM; CLOPIDOGREL; CLOZAPINE; CODEINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DAPSONE; DESIPRAMINE; HYDROCORTISONE; UNINDEXED DRUG;

ACCURACY; COMPUTER ANALYSIS; DATA ANALYSIS; DECISION MAKING; DRUG ACCUMULATION; DRUG INTERACTION; DRUG METABOLISM; DRUG RESEARCH; DRUG TRANSFORMATION; ENZYME INDUCTION; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; METHODOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW;

COMPUTERS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; PHARMACOKINETICS; RESEARCH DESIGN;

EID: 0034794222     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140090-00001     Document Type: Review

References (48)

1. Drug-drug interactions of new active substances: Mibefradil example
2. P450 superfamily: Update on new sequence, gene mapping, accession number and nomenclature
3. Molecular genetics of the human cytochrome P450 monooxygenase superfamily
4. Human cytochrome P450 enzymes
5. The human hepatic cytochromes P450 involved in drug metabolism
6. Inhibition and induction of human cytochrome P450 (CYP) enzymes
7. Update: Clinically significant cytochrome P-450 drug interactions
8. Role of cytochrome P450 enzymes in drug-drug interactions
9. Assessment and reporting of clinical pharmacology information in drug labelling
10. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: Study design and data analysis issues
11. Human cytochrome P450 enzymes expressed in bacteria: Reagents to probe molecular interactions in toxicology
12. Cytochrome P450 expression systems
13. Recombinant yeast in drug metabolism
14. Design of in vitro studies to predict in vivo inhibitory drug-drug interactions
15. Cytochrome P450 enzymes and drug metabolism - Basic concepts and methods of assessment
16. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes
17. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
18. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
19. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human microsomes
20. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
21. Clinical importance of hepatic cytochrome P450 in drug metabolism
22. The cytochrome P450 enzyme system and its effect on drug metabolism
23. Clinically significant drug interactions
24. Quantitative drug interactions prediction system (Q-DIPS): A computer-based prediction and management support system for drug metabolism interactions
25. Application of human liver microsomes in metabolism-based drug-drug interactions: In vitro-in vivo correlations and the Abbott laboratories experience
26. In vivo approaches to predicting drug interactions in vivo
27. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport
28. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data
29. Inhibition and induction of cytochrome P450 and the clinial implications
30. Extrapolation of in vitro enzyme induction data to humans in vivo
31. Quantitative prediction of in vivo drug metabolism and interactions from in vitro data
32. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling
33. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol
34. Hepatic vectorial transport of xenobiotics
35. Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations
36. Uptake of organic anions by isolated rat hepatocytes. A classification in terms of ATP-dependency
37. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver
38. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine
39. Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells
40. Human cytochrome P450s: Selectivity and measurement in vivo
41. Presystemic extraction: Mechanisms and consequences
42. Interaction between cyclosporine and fluconazole in renal allograft recipients
43. Fluconazole-cyclosporine interaction: A dose-dependent effect?
44. Interaction of fluconazole with ciclosporin